Chargement en cours...
Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3893710/ https://ncbi.nlm.nih.gov/pubmed/24419064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182a7a97a |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|